Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.

ABSTRACT:

Background

The management of critically ill patients with coronavirus disease 2019 (COVID-19), caused by a new human virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is challenging. Recently, there have been several reports with inconsistent results after treatment with convalescent plasma (CP) on critically ill patients with COVID-19, which was produced with a neutralizing antibody titer and tested in a P3 or P4 laboratory. However, due to the limitation of the conditions on mass production of plasma, most producers hardly had the capability to isolate the neutralizing antibody. Here, we report the clinical courses of three critically ill patients with COVID-19 receiving CP treatments by total immunoglobulin G (IgG) titer collection.

Methods

Three patient

SUBMITTER: Liu M 

PROVIDER: S-EPMC7436937 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature